Oliver M Grauer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9230449/publications.pdf

Version: 2024-02-01

77 papers	6,387 citations	147801 31 h-index	91884 69 g-index
81 all docs	81 docs citations	81 times ranked	11322 citing authors

#	Article	IF	Citations
1	A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain, 2023, 146, 977-990.	7.6	10
2	Classical and disease-specific quality indicators in glioma surgeryâ€"Development of a quality checklist to improve treatment quality in glioma patients. Neuro-Oncology Practice, 2022, 9, 59-67.	1.6	0
3	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapyâ€"the MecMeth/NOA-24 trial. Trials, 2022, 23, 57.	1.6	10
4	Combined Fluorescence-Guided Resection and Intracavitary Thermotherapy with Superparamagnetic Iron-Oxide Nanoparticles for Recurrent High-Grade Glioma: Case Series with Emphasis on Complication Management. Cancers, 2022, 14, 541.	3.7	5
5	Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas. Scientific Reports, 2022, 12, 6769.	3.3	10
6	The genetic landscape of choroid plexus tumors in children and adults. Neuro-Oncology, 2021, 23, 650-660.	1.2	26
7	Predicting postoperative seizure development in meningiomas â€“ Analyses of clinical, histological and radiological risk factors. Clinical Neurology and Neurosurgery, 2021, 200, 106315.	1.4	6
8	<scp>MGMT</scp> promoter methylation analysis for allocating combined <scp>CCNU</scp>/<scp>TMZ</scp> chemotherapy: Lessons learned from the <scp>CeTeG</scp>/<scp>NOA</scp>â€09 trial. International Journal of Cancer, 2021, 148, 1695-1707.	5.1	11
9	Combination of ALA-induced fluorescence-guided resection and intraoperative open photodynamic therapy for recurrent glioblastoma: case series on a promising dual strategy for local tumor control. Journal of Neurosurgery, 2021, 134, 426-436.	1.6	53
10	Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT. Journal of Neurosurgery, 2021, 135, 845-854.	1.6	6
11	Toxicity Reduction after Craniospinal Irradiation via Helical Tomotherapy in Patients with Medulloblastoma: A Unicentric Retrospective Analysis. Cancers, 2021, 13, 501.	3.7	4
12	BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi11-vi11.	1.2	0
13	The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). Frontiers in Immunology, 2021, 12, 787307.	4.8	21
14	Brain invasion in meningiomas: does surgical sampling impact specimen characteristics and histology?. Neurosurgical Review, 2020, 43, 793-800.	2.4	12
15	An enigmatic case of cortical anopsia: Antemortem diagnosis of a 14-3-3 negative Heidenhain-variant MM1-sCJD. Prion, 2020, 14, 24-28.	1.8	2
16	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. Journal of Neuro-Oncology, 2020, 148, 117-130.	2.9	12
17	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro-Oncology, 2020, 22, 1030-1043.	1.2	35
18	Multimodal Molecular Imaging of the Tumour Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1225, 71-87.	1.6	20

#	Article	IF	Citations
19	Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2131-2141.	6.4	14
20	Risk factors for preoperative seizures in intracranial meningiomas. Journal of Neurosurgical Sciences, 2020, , .	0.6	1
21	Is Visible Aminolevulinic Acid-Induced Fluorescence an Independent Biomarker for Prognosis in Histologically Confirmed (World Health Organization 2016) Low-Grade Gliomas?. Neurosurgery, 2019, 84, 1214-1224.	1.1	54
22	Diagnostic impact of additional O-(2-[18F]fluoroethyl)-L-tyrosine (18F-FET) PET following immunotherapy with dendritic cell vaccination in glioblastoma patients. British Journal of Neurosurgery, 2019, , 1-7.	0.8	11
23	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 2019, 7, 1910-1927.	3.4	74
24	Interdisciplinary Decision Making in Hemorrhagic Stroke Based on CT Imagingâ€"Differences Between Neurologists and Neurosurgeons Regarding Estimation of Patients' Symptoms, Glasgow Coma Scale, and National Institutes of Health Stroke Scale. Frontiers in Neurology, 2019, 10, 997.	2.4	4
25	Health-related quality of life and neurocognitive functioning with lomustineâ€"temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 1444-1453.	10.7	29
26	Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain, 2019, 142, 3411-3427.	7.6	39
27	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOAâ€"09): a randomised, open-label, phase 3 trial. Lancet, The, 2019, 393, 678-688.	13.7	384
28	ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL. Neuro-Oncology, 2019, 21, vi25-vi26.	1.2	0
29	Ineffective treatment of PML with pembrolizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e627.	6.0	39
30	Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination. International Journal of Molecular Sciences, 2019, 20, 5985.	4.1	8
31	Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. Journal of Neuro-Oncology, 2019, 141, 83-94.	2.9	102
32	Brain invasion and the risk of seizures in patients with meningioma. Journal of Neurosurgery, 2019, 130, 789-796.	1.6	48
33	SURG-12. â€œNANOPASTEâ€•THERAPY AS POTENTIAL TREATMENT OPTION FOR RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi242-vi242.	1.2	0
34	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. Neuro-Oncology, 2018, 20, 975-985.	1.2	11
35	Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 422-425.	1.7	57
36	QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA. Neuro-Oncology, 2018, 20, vi218-vi219.	1.2	0

#	Article	IF	Citations
37	A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials, 2018, 19, 293.	1.6	27
38	A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. Frontiers in Neurology, 2018, 9, 383.	2.4	6
39	The evolution of cranial meningioma surgeryâ€"a single-center 25-year experience. Acta Neurochirurgica, 2018, 160, 1801-1812.	1.7	27
40	Targeting B cells in relapsingâ€"remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic Advances in Neurological Disorders, 2017, 10, 51-66.	3.5	62
41	SURG-32. COMBINED INTRACAVITARY THERMOTHERAPY WITH IRON-OXIDE NANOPARTICLES AND RADIOTHERAPY AS AÂPROMISING TREATMENT MODALITY IN RECURRENT GBM. Neuro-Oncology, 2017, 19, vi241-vi242.	1.2	0
42	ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. Neuro-Oncology, 2017, 19, vi13-vi14.	1.2	17
43	Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia. Cancer Research and Treatment, 2017, 49, 548-552.	3.0	31
44	Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab Â± ipilimumab: CheckMate 143.. Journal of Clinical Oncology, 2017, 35, 2001-2001.	1.6	2
45	RTHP-22. INFLAMMATORY RESPONSE AFTER MODIFIED NANOTHERM AND RADIOTHERAPY OF RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi178-vi179.	1.2	6
46	CD4⁺T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology, 2016, 18, 807-818.	1.2	129
47	Ibuprofen and Diclofenac Restrict Migration and Proliferation of Human Glioma Cells by Distinct Molecular Mechanisms. PLoS ONE, 2015, 10, e0140613.	2.5	54
48	QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143. Neuro-Oncology, 2015, 17, v189.2-v189.	1.2	0
49	Neurocognitive decline in HIV patients is associated with ongoing Tâ€cell activation in the cerebrospinal fluid. Annals of Clinical and Translational Neurology, 2015, 2, 906-919.	3.7	40
50	CBIO-19IBUPROFEN AND DICLOFENAC INHIBIT MIGRATION AND PROLIFERATION OF HUMAN GLIOMA CELL LINES IN VITRO. Neuro-Oncology, 2015, 17, v58.5-v59.	1.2	0
51	The role of ion channels in malignant brain tumors. Journal of Neuro-Oncology, 2015, 125, 225-235.	2.9	15
52	Glioma Tissue Obtained by Modern Ultrasonic Aspiration with a Simple Sterile Suction Trap for Primary Cell Culture and Pathological Evaluation. European Surgical Research, 2014, 53, 37-42.	1.3	14
53	Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model. International Journal of Cancer, 2013, 132, 843-853.	5.1	77
54	Benefits of contrast-enhanced SWI in patients with glioblastoma multiforme. European Radiology, 2013, 23, 2868-2879.	4.5	24

#	Article	IF	Citations
55	New Aspects of an Old Drug â€“ Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells. PLoS ONE, 2013, 8, e66987.	2.5	86
56	Muscle Cramps and Neuropathies in Patients with Allogeneic Hematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. PLoS ONE, 2012, 7, e44922.	2.5	28
57	Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05). Journal of Neuro-Oncology, 2011, 104, 801-809.	2.9	10
58	Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain, 2010, 133, 2852-2865.	7.6	189
59	Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients?. , 2010, , 133-157.		2
60	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology, 2009, 11, 394-402.	1.2	203
61	RNOP-09: Pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a phase II study. BMC Cancer, 2009, 9, 308.	2.6	83
62	Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments. Brain Pathology, 2009, 19, 674-693.	4.1	2,884
63	Recurrent cardiac arrest caused by lateral medulla oblongata infarction. BMJ Case Reports, 2009, 2009, bcr0220091625-bcr0220091625.	0.5	16
64	Bilateral vertebral artery occlusion with retrograde basilary flow in three cases of giant cell arteritis. BMJ Case Reports, 2009, 2009, bcr0720080488-bcr0720080488.	0.5	8
65	Elimination of regulatory T cells is essential for an effective vaccination with tumor lysateâ€pulsed dendritic cells in a murine glioma model. International Journal of Cancer, 2008, 122, 1794-1802.	5.1	78
66	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	2.9	24
67	TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas. Journal of Immunology, 2008, 181, 6720-6729.	0.8	127
68	In vivo Colocalization of Antigen and CpG within Dendritic Cells Is Associated with the Efficacy of Cancer Immunotherapy. Cancer Research, 2008, 68, 5390-5396.	0.9	55
69	CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responsesin vivo. International Journal of Cancer, 2007, 121, 95-105.	5.1	199
70	Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-Î²2. Journal of Neuro-Oncology, 2007, 82, 151-161.	2.9	37
71	Toll-like receptors on regulatory T cells: expanding immune regulation. Trends in Immunology, 2006, 27, 387-393.	6.8	194
72	Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. Journal of Neuroimmunology, 2004, 148, 63-73.	2.3	64

#	Article	IF	Citations
73	Maintenance Therapy with 13-cis Retinoid Acid in High-Grade Glioma at Complete Response After First-Line Multimodal Therapy â€“ A Phase-II Study. Journal of Neuro-Oncology, 2004, 68, 79-86.	2.9	22
74	Pegylated liposomal doxorubicinâ€efficacy in patients with recurrent highâ€grade glioma. Cancer, 2004, 100, 1199-1207.	4.1	189
75	Salvage therapy in patients with glioblastoma. Cancer, 2003, 98, 2678-2686.	4.1	63
76	Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochemistry and Cell Biology, 2002, 117, 351-362.	1.7	48
77	Microglial Phagocytosis of Apoptotic Inflammatory T Cells Leads to Down-Regulation of Microglial Immune Activation. Journal of Immunology, 2001, 167, 5004-5010.	0.8	128